CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
Biotech partner would develop Enveric's three classes of compounds from its AI-powered drug discovery platform. Licensee to receive exclusive global licenses to develop and sublicense the three assets ...
Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results